S. Rodríguez

发表

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

F. Prósper, R. Valdés-Mas, Diana A. Puente, 2020, Leukemia.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

R. Advani, Sonali M. Smith, K. Kolibaba, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19

Paloma Martin, C. Rodriguez-Gonzalez, P. Escribano, 2022, BMC Infectious Diseases.

Imaging of the pleura: tumorlike conditions, primary tumors and metastases

S. Rodríguez, Carlos A Garcia, J. Castro, 2018 .

Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes

F. Prósper, A. Órfão, N. Puig, 2019, Blood.

Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis

E. Giné, A. López-Guillermo, T. Baumann, 2015, Blood Cancer Journal.

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma.

J. Martinez-Climent, A. Órfão, N. Puig, 2020, Blood.

Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

J. Martinez-Climent, F. Prósper, N. Puig, 2022, Science advances.

Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma.

H. Goldschmidt, F. Prósper, A. Órfão, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tumor cells in light-chain amyloidosis and myeloma show different transcriptional rewiring of normal plasma cell development.

I. Amit, A. Weiner, F. Prósper, 2021, Blood.

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

J. Martinez-Climent, F. Prósper, R. Valdés-Mas, 2020 .

The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial

R. Advani, K. Blum, Michael E. Williams, 2011 .

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

Marco S. Nobile, D. Besozzi, N. Puig, 2023, Nature communications.

Single-Cell Characterization of Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-negative T cells as Potential Tumor-Reactive Lymphocytes

Cristina Pérez Ruiz, F. Prósper, A. Órfão, 2019, Clinical Lymphoma Myeloma and Leukemia.

Lymphoma of the central nervous system: patterns of disease and imaging findings.

S. Rodríguez, A. Granados, J. Orejuela, 2017 .